Immunofluorescence Assay Market
                     Immunofluorescence Assay 
Market
Global Forecast to 2026
Immunofluorescence Assay 
Market is expected to reach 
$3.5 Billion by 2026
Growing at a 
CAGR of  6.0% (2021 – 2026)
Immunofluorescence Assay Market by Product (Reagent, Instruments, Antibodies, 
Kits, Consumables & Accessories), Type (Direct, Indirect), Disease (Infectious 
Disease, Other Diseases), End User (Contract Research Organizations) – Global 
Forecast to 2026
View detailed Table of Content here -
 https://www.marketsandmarkets.com/Market-Reports/immunofluorescence-assay-market
-255585571.html
Key Market Players
The major players operating in this market are Thermo Fisher Scientific, Inc. 
(US), Abcam plc (UK), Bio-Rad Laboratories, Inc. (US), PerkinElmer Inc. 
(US), Merck KGaA (Germany), Werfen Company (Spain), Cell Signaling 
Technology, Inc. (US), MEDIPAN GmbH (Germany), Sino Biological, Inc. 
(China), Danaher Corporation (US), Maravai LifeSciences (US), Enzo 
Biochem, Inc. (US)
Thermo Fisher is a leading player in the immunofluorescence assays market due to its 
extensive portfolio of primary antibodies, secondary antibodies, reagents, and 
instruments. The company offers customers a complete range of analytical instruments 
as well as laboratory equipment, consumables, and reagents. The company also has a 
strong geographic footprint serving pharmaceutical and biotechnology companies, 
hospitals and clinical diagnostic laboratories, universities, research institutes, and 
government agencies. The company pursues the strategy of acquisitions. In 2018, the 
company acquired BD, which helped it to broaden its Life Sciences Solutions’ portfolio. 
The company aims to expand its customer base in the emerging and high-growth 
regions.
Danaher Corporation (US) accounted for the largest share of the immunofluorescence 
instruments market in 2019. The company offers microscopes through Leica 
Microsystems. To sustain its foothold and increase its share in the market, the company 
pursues inorganic growth strategies. In this regard, in 2017, Leica Biosystems partnered 
with the Kuwait Ministry of Health through its distributor, Technical Services Supplies 
Trading & Contracting Company, W.L.L., to provide Kuwait with Digital Pathology (DP) 
as its standard of care.